Fenwick Advises Sema4 on SPAC Merger with CM Life Sciences

Fenwick & West is representing Sema4, a patient-centered clinical data intelligence company, in its merger agreement with CM Life Sciences.

White & Case is advising CM Life Sciences, a special purpose acquisition company, on the transaction. The company is sponsored by affiliates of institutional investors Casdin Capital LLC and Corvex Management LLP.

The transaction places Sema4 at an enterprise value of about $2 billion. It is expected to provide the combined company with up to $793 million, of which up to $343 million will be paid to Sema4 stockholders.

Sema4, whose platform is powered by artificial intelligence and machine learning, ...